Serum Uromodulin and All-Cause Mortality in Peritoneal Dialysis Patients: A Chinese Cohort Study

Dominik Steubl, Li Fan, Yunfang Zhang, Fei Xiong, Hongbo Li, Hao Zhang, Jing Hu, Amy B. Karger, Lesley A. Inker, Xueqing Yu, Andrew S. Levey

Research output: Contribution to journalArticlepeer-review

2 Scopus citations
Original languageEnglish (US)
Article number100536
JournalKidney Medicine
Volume4
Issue number10
DOIs
StatePublished - Oct 2022

Bibliographical note

Funding Information:
Grant 2002B60118 from Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China; Operational grant 2017B030314019 of Guangdong Provincial Key Laboratory; Paul Teschan Research Fund – Dialysis Clinic Inc (“Monitoring PD Adequacy Using Serum Levels of Endogenous Filtration Marker”); and Driscoll Family Endowed Fund in Nephrology, Tufts Medical Center, Boston, Massachusetts.

Funding Information:
Research idea and study design: DS, LF, ASL; data acquisition: YZ, FX, HL, HZ, JH; sUMOD measurement: ABK; data analysis/interpretation: DS, LF, ASL, LAI, XY. DS and LF contributed equally to the manuscript. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. Grant 2002B60118 from Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, China; Operational grant 2017B030314019 of Guangdong Provincial Key Laboratory; Paul Teschan Research Fund – Dialysis Clinic Inc (“Monitoring PD Adequacy Using Serum Levels of Endogenous Filtration Marker”); and Driscoll Family Endowed Fund in Nephrology, Tufts Medical Center, Boston, Massachusetts. The authors declare that they have no relevant financial interests. Received March 27, 2022 as a submission to the expedited consideration track with 2 external peer reviews. Direct editorial input from the Statistical Editor and an Associate Editor who served as Acting Editor-in-Chief. Accepted in revised form August 3, 2022. The involvement of an Acting Editor-in-Chief was to comply with Kidney Medicine's procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies.

Cite this